Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AMC Networks Inc (AMCX) & The Rest of Friday’s Top Upgrades & Downgrades

This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines include upgrades for both AMC Networks Inc (NASDAQ:AMCX) and Bankrate Inc (NYSE:RATE), but a downgrade for LabCorp Holdings. Let’s dive right in.

AMC Networks Inc (NASDAQ:AMCX)

AMC no longer among the “walking dead”
First up, barely a week has passed since AMC Networks Inc (NASDAQ:AMCX) confirmed that the season finale of The Walking Dead scored a record-high viewership for the series. Now, analysts at B. Riley & Co. think they see signs of life in AMC shares. On Friday, B. Riley removed its sell rating from AMC stock, upgrading the shares to “neutral” and assigning a $61 price target.

Forgive investors if they’re not exactly jumping out of their coffins with enthusiasm for the upgrade, though. After all, AMC  already costs more than $65 a share, so a prediction that the shares might be worth $61 a year from now is hardly cause for rejoicing.

But here’s the thing: AMC Networks Inc (NASDAQ:AMCX) investors might have more to get excited about, if they focus less on what analysts are saying and more on the numbers. Last year, AMC generated $550 million in real free cash flow from its business — four times the amount of “GAAP” profit it is permitted to report. This gives the stock a price-to-free cash flow ratio of just 8.6. It suggests that if AMC succeeds in hitting projected targets for profits growth — 21% — the shares could be worth far more than the $65 they currently cost… and deserve a far better rating than just “neutral.”

Bank on Bankrate?
A more enthusiastic upgrade appeared this morning from analysts at Stifel Nicolaus, who had kind words for mortgage and credit card info provider Bankrate Inc (NYSE:RATE). Stifel thinks the stock — currently at $12 and change — should be worth $17 in a year.

But while Stifel’s on the right track here, $17 might be a bit of a stretch. You see, Bankrate may look expensive at 44 times earnings. But with free cash flow that exceeds reported net income by a factor of two, it’s probably more accurate to think of the stock as selling for “20 times cash profits” than as costing “44 times earnings.”

Fact is, with a 22.5% projected long-term growth rate, Bankrate probably is a bit undervalued at today’s prices. It probably is worth buying. Just don’t go banking on the 35% profit that Stifel is promising you. Absent another burst of irrational exuberance in an already overheated market, it’s not going to happen. Bankrate’s worth more than it costs today… but not that much more.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.